Research Article

Mean Corpuscular Volume as a Predictive Factor of Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer

Wen-Yi Zhang, Xing-Xing Chen, Wen-Hao Chen, Hui Zhang, and Chang-Lin Zou

Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Correspondence should be addressed to Chang-Lin Zou; zcl19670115@163.com

Received 8 November 2017; Revised 28 January 2018; Accepted 13 February 2018; Published 18 March 2018

Academic Editor: Haruhiko Sugimura

Copyright © 2018 Wen-Yi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The aim of this study was to identify if blood routine parameters and serum tumor marker are potential predictive factors for tumor response to preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer. Materials and Methods. 55 locally advanced rectal cancer patients were treated with preoperative CRT in this study. The total dose of preoperative radiotherapy was 45 Gy in 25 fractions of 1.8 Gy in 5 weeks. All patients concurrently received 825 mg/m² capecitabine orally twice daily on days 1 to 14 and 22 to 35. Total mesorectal excision (TME) was performed 6 weeks after the end of preoperative CRT. Blood routine examination and serum tumor marker were checked before preoperative CRT. Tumor response to preoperative CRT was evaluated with the semiquantitative tumor regression grading (TRG) system proposed by Dworak criteria according to histopathological examination of the surgical specimens. Univariable and multivariable logistic regression analyses were used to test the association between blood routine parameters and serum tumor marker and tumor response to preoperative CRT. Results. Univariate logistic regression analysis revealed that differentiation, lymphocyte, LMR, MCV, PLR, and CEA have been significantly associated with tumor response to preoperative CRT. Multivariate logistic regression analysis revealed that differentiation, MCV, and CEA were the predictors of tumor response to preoperative CRT. According to the ROC analysis, the AUC of differentiation, MCV, and CEA was 0.794, 0.802, and 0.723, respectively. Optimal cutoff points for MCV and CEA were 87.65 fl and 4.05 ng/ml, respectively. Conclusion. MCV is a potential predictive factor for tumor response to preoperative chemoradiation in locally advanced rectal cancer.

1. Introduction

Rectal cancer is one of the most common cancers in the world [1]. For patients with locally advanced rectal cancers (stage II to III), preoperative chemoradiotherapy (CRT) followed by radical surgery is currently used worldwide and considered the gold standard regimen [2]. Pathological complete response (pCR) and pathological partial response (pPR) rates in locally advanced rectal cancer patients with preoperative CRT followed by radical surgery are approximately 25% and 60%, respectively [3]. However, for patients with stable disease (SD) or progressive disease (PD), this treatment regimen may have disadvantages such as promoting disease progression or delaying surgery and meanwhile affected resectability, local control rates, disease-free survival, and overall survival [4]. This study attempts to assess the relationship between pathological reaction and clinical factors and blood routine parameters in patients with locally advanced rectal cancer who received preoperative CRT followed by radical surgery.

2. Materials and Methods

2.1. Patients. This retrospective study was conducted using the database from the patients with stage II to III rectal cancer who received preoperative CRT followed by radical surgery from 2014 through 2016. This study was approved by the Ethics Committee of the First Affiliated Hospital of
as complete regression [5, 6]. The "no response group" included 15 (27.2%) patients with TRG 2, 12 (21.8%) patients with TRG 1, and 2 (3.6%) patients with TRG 0. 5 patients (9.1%) and 4 patients (7.3%) were female in the "response group" and the "no response group," respectively. And the median age in the "response group" and the "no response group" was 60 years and 57 years, respectively. All patients’ tumors was adenocarcinoma. Patient characteristics and blood routine parameters were shown in Table 1.

Univariate logistic regression analysis revealed that different factors were as follows: age, sex, differentiation, lymphocyte, LMR, MCV, PLR, and CEA have been significantly associated with tumor response to preoperative CRT. Multivariate logistic regression analysis revealed that differentiation (OR 0.056 (95% CI 0.004–0.889), p = 0.041), MCV (OR 0.615 (95% CI 0.401–0.942), p = 0.025), and CEA (OR 1.639 (95% CI 1.126–2.386), p = 0.010) were the predictors of tumor response to preoperative CRT. Tables 2 and 3 show the logistic regression model for prediction of tumor response to preoperative CRT. According to the ROC analysis, the AUC of differentiation, MCV, and CEA was 0.794, 0.802, and 0.723, respectively. Optimal cutoff points for MCV and CEA were 87.65 fl and 4.05 ng/ml, respectively. The ROC curve is shown in Figure 1.

According to the optimal cutoff point of MCV, the patients were classified into two groups, the high MCV and low MCV groups. It is found that patients in the "response group" were the majority of the high MCV group (88.46% versus 11.54%) and patients in the "no response group" were the majority of the low MCV group (65.52% versus 34.48%).

According to the optimal cutoff point of CEA, the patients were classified into two groups, the high CEA and low CEA groups. It is found that patients in the "response group" were the majority of the low CEA group (76.92% versus 23.08%) and patients in the "no response group" were the majority of the high CEA group (72.41% versus 27.59%).

### 4. Discussion

In this study, there was a significant association between elevated levels of MCV and good tumor response to preoperative chemoradiation in advanced rectal cancer. There was a significant association between decreased levels of CEA and good tumor response to preoperative chemoradiation. Additionally, remarkable significance was reached for differentiation. The tumor with low differentiation had good response to preoperative chemoradiation. The percentage of patients in TRG 0, TRG 1, TRG 2, TRG 3, and TRG 4 in our study was approximately close to other studies [6, 7].

Dellapasqua and colleagues [8] reported that elevated MCV was related to decreased risk of disease progression in patients treated with chemotherapy for metastatic breast cancer. Cokmert and colleagues [9] reported that increased MCV may be used as a predictor of improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer who were treated with...
| Variable                                | Response (26) | No response (29) | \( p \)   |
|-----------------------------------------|---------------|------------------|----------|
| **Sex**                                 |               |                  |          |
| Female                                  | 5             | 4                | 0.721    |
| Male                                    | 21            | 25               |          |
| **Age (y)**                             |               |                  |          |
| Median (range)                          | 60 (38–88)    | 57 (31–87)       | 0.145    |
| **Differentiation**                     |               |                  |          |
| Low                                     | 14            | 3                | <0.001   |
| Moderate                                | 10            | 12               |          |
| High                                    | 2             | 14               |          |
| **White blood cell count (\( \times 10^9 \))** |               |                  |          |
| Median (range)                          | 6.20 (3.89–12.50) | 6.46 (3.27–12.44) | 0.416    |
| **Neutrophil granulocyte (\( \times 10^9 \))** |               |                  |          |
| Median (range)                          | 3.62 (2.36–10.20) | 4.20 (1.79–10.70) | 0.434    |
| **Monocyte (\( \times 10^9 \))**       |               |                  |          |
| Median (range)                          | 0.50 (0.26–0.90) | 0.59 (0.15–1.07)  | 0.142    |
| **Lymphocyte (\( \times 10^9 \))**     |               |                  |          |
| Median (range)                          | 1.91 (0.80–3.90) | 1.40 (0.80–3.02)  | 0.017    |
| **Eosinophilic granulocyte (\( \times 10^9 \))** |               |                  |          |
| Median (range)                          | 0.11 (0–0.50)  | 0.14 (0–0.44)    | 0.195    |
| **Basophilic granulocyte (\( \times 10^9 \))** |               |                  |          |
| Median (range)                          | 0.015 (0–0.10) | 0 (0–0.04)       | 0.050    |
| **Neutrophil-to-lymphocyte ratio (NLR)** |               |                  |          |
| Median (range)                          | 2.08 (1.02–12.75) | 2.91 (0.99–11.89) | 0.085    |
| **Lymphocyte-to-monocyte ratio (LMR)**  |               |                  |          |
| Median (range)                          | 3.69 (1.00–9.75) | 2.40 (1.05–6.49)  | 0.024    |
| **Neutrophil-to-monocyte ratio (NMR)**  |               |                  |          |
| Median (range)                          | 7.24 (3.27–20.35) | 8.01 (2.27–26.50) | 0.837    |
| **Hemoglobin (g/l)**                    |               |                  |          |
| Median (range)                          | 133.50 (83.00–158.00) | 137.00 (96.00–168.00) | 0.294    |
| **Hematocrit (HCT) (l/l)**              |               |                  |          |
| Median (range)                          | 0.40 (0.26–0.46) | 0.39 (0.30–0.50)  | 0.329    |
| **Mean corpuscular volume (MCV) (fl)**  |               |                  |          |
| Median (range)                          | 92.20 (77.70–98.00) | 85.90 (63.30–96.10) | &lt;0.001 |
| **Red cell distribution width (RDW) (%)** |               |                  |          |
| Median (range)                          | 12.95 (11.80–20.80) | 13.10 (11.80–18.00) | 0.712    |
| **Platelet (\( \times 10^9 \))**       |               |                  |          |
| Median (range)                          | 212.50 (123.00–656.00) | 235.00 (116.00–501.00) | 0.554    |
| **Platelet-to-lymphocyte ratio (PLR)**  |               |                  |          |
| Median (range)                          | 115.71 (51.25–381.25) | 136.40 (74.09–357.89) | 0.006    |
| **Thrombocytocrit (g/l)**               |               |                  |          |
| Median (range)                          | 0.21 (0.12–0.42) | 0.24 (0.15–0.50)  | 0.303    |
| **CEA (ng/ml)**                         |               |                  |          |
| Median (range)                          | 2.85 (0.30–9.50) | 4.90 (0.60–27.70) | 0.002    |
| **AFP (ng/ml)**                         |               |                  |          |
| Median (range)                          | 2.53 (1.36–11.90) | 2.70 (1.60–10.53) | 0.727    |
| **CA199 (ng/ml)**                       |               |                  |          |
| Median (range)                          | 12.50 (0.80–2153.70) | 7.60 (0.80–4269.70) | 0.864    |
The reduced ratio of hypoxic tumor cell playing an important role in chemoradioresistance [14]. Finally, there is an increasing chemoradiosensitivity in tumor tissue.

Some studies reported that CEA level is a predictor of tumor response to preoperative CRT in rectal cancer. Das et al. [15] reported that CEA level, circumferential extent of tumor, and distance from the anal verge may be used to predict the pathologic response to preoperative chemoradiation for patients with rectal cancer. Park et al. [16] reported that elevated serum CEA levels in rectal adenocarcinoma patients are associated with poor response to CRT. Park and colleagues [17] have evaluated the relationship between serum CEA and tumor response in rectal cancer patients treated with preoperative CRT. They found [17] that the good response was significantly associated with the lower level of pre-CRT CEA. Restivo and colleagues [18] noticed that there was a significant correlation between serum CEA lower than 5 ng/dl and complete pathological response after preoperative treatment in patients with rectal cancer. Similarly, this study found that serum CEA level in patients with good tumor response to preoperative CRT was significantly lower than that in patients with no response.

Benej and colleagues [19] reported that left upper lobe non-small cell lung cancer patients with WBC lower than $10 \times 10^9$/l on the third day after the operation had significantly higher overall survival than peer with WBC count higher than $10 \times 10^9$/l. Peng and colleagues [20] reported that there was a significant association between neutrophil, monocyte, lymphocyte, red blood cell count, NLR, LMR, and risk of colorectal cancer mortality. Taussky and colleagues [21] reported that a posttreatment high WBC and lymphocyte count increases the overall mortality of localized prostate cancer patients receiving radiotherapy. Li and colleagues [22] reported that postoperative high NLR was associated with poor recurrence-free survival in patients with epithelial ovarian cancer. Qin and colleagues [23] reported that patients with ovarian cancer had significantly absolute neutrophil count, NLR, and PLR than normal population. However, we did not identify that WBC, NLR, and LMR could predict tumor response to preoperative CRT.

Wei and colleagues [24] reported that higher RDW levels were significantly higher in the gastric cancer patients than in normal population. Ay and colleagues [25] reported that RDW levels in patients with colon cancer were significantly higher than its level in patients with colon polyp. Kust and colleagues [26] reported that RDW levels both pre- and postoperative had significantly absolute neutrophil count, NLR, and PLR than normal population. However, we did not identify that WBC, NLR, and LMR could predict tumor response to preoperative CRT.

5. Conclusions

Our research identified MCV as a potential predictive factor that may allow personalization of preoperative CRT in locally
advanced rectal cancer. However, more investigation and larger samples of patients in locally advanced rectal cancer are needed further to confirm the relevance of this result.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Acknowledgments**

Financial support was received from the Public Welfare Science and Technology Plan Projects of Wenzhou (Y20150217).

**References**

[1] I. J. Park, Y. N. You, A. Agarwal et al., "Neoadjuvant treatment response as an early response indicator for patients with rectal cancer," *Journal of Clinical Oncology*, vol. 30, no. 15, pp. 1770–1776, 2012.

[2] J. Kitayama, K. Yasuda, K. Kawai, E. Sunami, and H. Nagawa, “Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer,” *Radiation Oncology*, vol. 5, no. 1, p. 47, 2010.

[3] K. M. Jang, S. H. Kim, D. Choi, S. J. Lee, M. J. Park, and K. Min, "Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results," *The British Journal of Radiology*, vol. 85, no. 1017, pp. e566–e572, 2012.

[4] F. M. Vecchio, V. Valentini, B. D. Minsky et al., “The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer,” *International Journal of Radiation Oncology, Biology, Physics*, vol. 62, no. 3, pp. 752–760, 2005.

[5] O. Dworak, L. Keilholz, and A. Hoffmann, “Pathological features of rectal cancer after preoperative radiochemotherapy,” *International Journal of Colorectal Disease*, vol. 12, no. 1, pp. 19–23, 1997.

[6] A. A. Martoni, F. Di Fabio, C. Pinto et al., "Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer," *Annals of Oncology*, vol. 22, no. 3, pp. 650–656, 2011.

[7] A. Ho-Pun-Cheung, E. Assenat, C. Bascoul-Mollevi et al., “A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer,” *The Pharmacogenomics Journal*, vol. 11, no. 6, pp. 437–443, 2011.

[8] S. Dellapasqua, V. Bagnardi, F. Bertolini et al., “Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab,” *The Breast*, vol. 21, no. 3, pp. 309–313, 2012.

[9] S. Cokmert, L. Demir, A. Can et al., “Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer,” *Journal of BUON*, vol. 19, no. 1, pp. 75–82, 2014.

[10] H. A. Jung, H. J. Kim, C. H. Maeng et al., “Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer,” *Cancer Research and Treatment*, vol. 47, no. 1, pp. 72–77, 2015.

[11] R. Achermann, S. Ohlert, J. Fidel et al., “Ultrasound guided, pre-radiation oxygen measurements using polarographic oxygen needle electrodes in spontaneous canine soft tissue sarcomas,” *In Vivo*, vol. 16, no. 6, pp. 431–437, 2002.

[12] S. Brunner-Agten, T. von Känel, B. Röthlisberger, C. Broquet, and A. R. Huber, “Hb Bakersfield (HBA1: c.151_152insGGAGCC): the insertion of Arg-His between codons 49 and 50 of the α1-globin chain leads to increased oxygen affinity,” *Hemoglobin*, vol. 41, no. 1, pp. 1–5, 2017.

[13] U. M. Reiss, P. Bensimhon, S. A. Zimmerman, and R. E. Ware, “Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease,” *American Journal of Hematology*, vol. 82, no. 8, pp. 740–743, 2007.
[14] J. L. O’Donnell, M. R. Joyce, A. M. Shannon, J. Harmey, J. Geraghty, and D. Bouchier-Hayes, “Oncological implications of hypoxia inducible factor-1α (HIF-1α) expression,” Cancer Treatment Reviews, vol. 32, no. 6, pp. 407–416, 2006.

[15] P. Das, J. M. Skibber, M. A. Rodriguez-Bigas et al., “Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer,” Cancer, vol. 109, no. 9, pp. 1750–1755, 2007.

[16] Y. A. Park, S. K. Sohn, J. Seong et al., “Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer,” Journal of Surgical Oncology, vol. 93, no. 2, pp. 145–150, 2006.

[17] J. W. Park, S. B. Lim, D. Y. Kim et al., “Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery,” International Journal of Radiation Oncology, Biology, Physics, vol. 74, no. 3, pp. 810–817, 2009.

[18] A. Restivo, L. Zorcolo, I. M. F. Cocco et al., “Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer,” Annals of Surgical Oncology, vol. 20, no. 3, pp. 864–871, 2013.

[19] M. Benej, I. Capov, J. Skrickova et al., “Association of the postoperative white blood cells (WBC) count in peripheral blood after radical surgical treatment of left upper lobe non-small cell lung cancer (NSCLC) with overall survival – single center results,” Bratislava Medical Journal, vol. 118, no. 5, pp. 299–301, 2017.

[20] F. Peng, D. Hu, X. Lin et al., “The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: the Fujian prospective investigation of cancer (FIESTA) study,” Journal of Cancer, vol. 8, no. 6, pp. 967–975, 2017.

[21] D. Taussky, D. Soulères, L. Azoulay et al., “A combination of testosterone and white blood cell count as a predictive factor of overall survival in localized prostate cancer,” Targeted Oncology, vol. 12, no. 5, pp. 695–701, 2017.

[22] Z. Li, N. Hong, M. Robertson, C. Wang, and G. Jiang, “Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer,” Scientific Reports, vol. 7, article 43001, 2017.

[23] Y. Qin, P. Wang, Z. Huang et al., “The value of red cell distribution width in patients with ovarian cancer,” Medicine, vol. 96, no. 17, article e6752, 2017.

[24] T. T. Wei, L. L. Wang, J. R. Yin et al., “Relationship between red blood cell distribution width, bilirubin, and clinical characteristics of patients with gastric cancer,” International Journal of Laboratory Hematology, vol. 39, no. 5, pp. 497–501, 2017.

[25] S. Ay, M. A. Eryilmaz, N. Aksoy, A. Okus, Y. Unlu, and B. Sevinc, “Is early detection of colon cancer possible with red blood cell distribution width?,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 2, pp. 753–756, 2015.

[26] D. Kust, M. Lucijanic, K. Urch et al., “Clinical and prognostic significance of anisocytosis measured as a red cell distribution width in patients with colorectal cancer,” QJM, vol. 110, no. 6, pp. 361–367, 2017.